Innovative Strategies and Recent Advances in Liver SurgeryView this Special Issue
Living-Donor Liver Transplantation and Hepatitis C
Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompression. In areas with low deceased-donor organ availability like Japan, living-donor liver transplantation (LDLT) is similarly indicated for HCV cirrhosis as deceased-donor liver transplantation (DDLT) in Western countries and accepted as an established treatment for HCV-cirrhosis, and the results are equivalent to those of DDLT. To prevent graft failure due to recurrent hepatitis C, antiviral treatment with pegylated-interferon and ribavirin is currently considered the most promising regimen with a sustained viral response rate of around 30% to 35%, although the survival benefit of this regimen remains to be investigated. In contrast to DDLT, many Japanese LDLT centers have reported modified treatment regimens as best efforts to secure first graft, such as aggressive preemptive antiviral treatment, escalation of dosages, and elongation of treatment duration.
Since the first successful application of living donor liver transplantation (LDLT) in 1990  and subsequent successful LDLT for adult recipient in 1994 , the use of live donors for liver transplantation has been widely applied to adult recipients where the availability of deceased-donors is severely restricted, like in Japan , and also accepted as a solution to the cadaveric donor shortage in Western countries .
End-stage liver disease caused by chronic hepatitis C virus (HCV) infection is the leading cause of liver transplantation in developed countries [5, 6], including Japan . Unfortunately, liver transplantation does not cure HCV-infected recipients, but re-infection of HCV universally occurs and disease progression is accelerated compared with that in the nontransplant population, resulting in poor outcomes for HCV-infected recipients .
The aim of this paper was to overview the current trends and controversies in LDLT for patients with HCV in relation to the perspectives from deceased-donor liver transplantation (DDLT).
2. Natural History of Hepatitis C after Orthotopic Liver Transplantation
Accumulating perspectives of disease recurrence in HCV-infected recipients have been obtained in DDLT within the last two decades. HCV reinfection occurs just after reperfusion followed by a rapid increase in HCV ribonucleic acid (RNA) levels within 4 postoperative months . The histologic features of liver injury usually resemble those of nontransplant HCV hepatitis typically developing after 3 months, but the clinical presentation, severity, and outcome are extremely heterogeneous and more profound compared to those in immune competent patients . Progression to cirrhosis usually takes 9 to 12 years after liver transplantation with a linear progression of histologic fibrosis [10, 11]. A less common, but well-documented, form of recurrence is called fibrosing cholestatic hepatitis (<10%), possibly mediated by a direct cytopathic mechanism under an extremely high viral load and immune-compromised condition. Graft failure occurs in 50% of recipients within a few months after fibrosing cholestatic hepatitis develops . Some HCV-reinfected recipients, however, show no apparent disease progression for at least the first decade and their graft injury remains mild or even absent despite a high viral burden.
Overall, cirrhosis develops in approximately 25% of liver transplant recipients (range 8% −44%) after 5 to 10 years and this percentage is likely to increase with an increase in the follow-up period [10, 11]. Once cirrhosis is complete, survival time is severely decreased and decompression is encountered with cumulative rates at 1 and 3 years of 40% and 60%, respectively, which finally results in graft failure [11, 13].
The development of decompensated cirrhosis due to recurrent hepatitis C is now the most frequent cause of graft failure, patient death, and the need for retransplantation in HCV-infected recipients [11, 13–17]. As a result, survival is significantly decreased compared with other indications, an overall 10% difference at 3 years . In the most recent United Network for Organ Sharing/Organ Procurement and Transplantation Network (UNOS/OPTN) study from the United States, 3-year survival is 78% among 7459 HCV-positive recipients compared with 82% among 20734 HCV-negative recipients (; http://www.unos.org) .
The poor outcome of HCV-positive recipients has resulted in the divergence in transplant outcomes between HCV-positive recipients and HCV-negative recipients. Improvements in organ preservation, surgical techniques, and postoperative care have dramatically improved the survival of HCV-negative recipients over the last two decades, whereas this has not been the case in HCV-positive recipients for whom outcome has remained unchanged or even worsened over time [19–22].
3. Current Status of LDLT
In areas with low deceased-donor organ availability like Japan, the indication of LDLT for HCV cirrhosis is similar to that of DDLT , whereas in Western countries, LDLT is conducted in an attempt to alleviate the shortage of donor organs and decrease the mortality among patients awaiting transplants, accounting for only 3% to 4% of all liver transplants .
According to the Japan Liver Transplantation Society , a total of 6097 LDLTs, comprising 98% of all liver transplants, have been performed till the end of 2010 in Japan. Among those, 3796 were adult cases including 1200 (32%) cases of HCV-related disease as a leading indication for adult LDLT. The 1, 3, 5, and 10 year survival rates of all adult LDLT and those of HCV-positive adults were 81%, 75%, 72%, and 66%, and 78%, 72%, 68%, and 59%, respectively, without difference.
4. LDLT as a Risk Factor for Recurrent Hepatitis C Studies Comparing Outcomes of LDLT and DDLT
Based on the significant negative impact of recurrent hepatitis C on recipients’ outcome, it is critical to identify the factors related to severe recurrent hepatitis C [8, 13]. In the transplant setting, many factors contribute to disease progression compared with nontransplant patients , including, viral-related factors [10, 27–36], donor age [17, 37–43], recipient-related factors [32, 44–49], graft and surgical factors [40, 50–57], and immunosuppressive agents [58–75] (Table 1) however, many aspects remain unclear and require further investigation . Among those, the possibility of increased severity of recurrent HCV in LDLT patients had been one of the hottest debates. The benefit of LDLT might be offset if the outcome of LDLT for HCV-positive recipients is worse than that of DDLT.
Early studies raised some negative concerns regarding the outcomes of LDLT in HCV patients, such as a poorer graft outcome and earlier and more aggressive HCV recurrence after LDLT compared with DDLT [144–146]. Several theories have been proposed to explain the differences in HCV recurrence between LDLT and DDLT recipients. One possible explanation is that the intense hepatocyte proliferation that occurs in partial liver grafts may lead to increased viral translation and replication [145, 147–149]. Genetic donor-recipient similarity is another proposed mechanism for more severe HCV recurrence [150, 151]. Recent studies, however, comparing outcomes of LDLT and DDLT in HCV-infected patients have not only failed to identify LDLT as a risk factor for more intense viral recurrence with impaired outcome, but also revealed improved results in LDLT recipients [39, 84–95], which do not support the aforementioned speculations. Alternatively, recent studies favored the theory that outcomes of LDLT for HCV cirrhosis could be better than those of DDLT due to the younger donor age and shorter ischemic time of LDLT grafts. The studies comparing outcomes between LDLT and DDLT in HCV-infected recipients are summarized in Table 2.
While several earlier studies demonstrated impaired patient/graft survival and severe histologic findings in LDLT [144–146], the majority of studies reported equal or even improved outcomes both in patient/graft survival and in fibrosis progression in LDLT [39, 84–95]. Since the large UNOS database study  demonstrated comparable short-term (24 months) survival between LDLT and DDLT, subsequent studies with considerable follow-up period have been published demonstrating comparable or even superior outcome in LDLT. Five-year patient survival ranged 71% to 84% in HCV-positive LDLT recipients among studies with sufficient follow-up period [39, 86, 94, 95]. Additionally, as Terrault et al.  reported, the learning curve for the LDLT procedure may have a considerable impact on the outcome of LDLT for HCV cirrhosis, which has been repeatedly pointed out by recent authors. Actually, none of reports after 2005 has found impaired outcome in LDLT.
These data should be interpreted with caution, however, because of the important clinical distinction between LDLT and DDLT. At the time of transplantation, DDLT recipients are far sicker than LDLT recipients as represented by a significantly higher MELD score, donor age is higher, and graft ischemic time is longer. Indeed, significantly poorer preoperative condition and older donor age in DDLT recipients were indicated in 7 and 6 studies, respectively, among 16 studies listed in Table 2. Additionally, cold ischemia time is significantly longer in DDLT than that in LDLT in all studies. All these factors, as presented in Table 1, are considered independent prognostic factors for severe HCV recurrence and impaired patient/graft outcome. Actually, Jain et al. , who recently reported that both patient/graft survival and histologic findings are better in LDLT, found in a subanalysis of the study that adjusting for MELD score (<25) and donor age (<50) resulted in similar outcomes.
Based on accumulating reports demonstrating comparable outcome of LDLT and DDLT for HCV cirrhosis, and refinement of surgical techniques and management in LDLT, hepatitis C recurrence by itself does not seem to explain the differences in patient/graft survival between LDLT and DDLT, and even improved outcomes could be achieved in LDLT due to the better quality of the graft, younger donors, and less sick recipient condition at the time of transplantation. Furthermore, based on these benefits of LDLT, donor selection to improve outcome of LDLT for HCV positive recipients could be assumed. Selecting younger donors  or donors with favorable IL-28B genotype [108, 109] could be possible future issues; however, with the severe lack of live donors, it seems impractical in clinical setting at present. Anyway, LDLT could be strongly recommended for HCV-positive patients whenever it is available.
5. Antiviral Treatment
Antiviral treatments for recurrent hepatitis C after liver transplantation include eradication of the HCV virus before transplantation with the use of pretransplant antiviral treatment, eradication of HCV virus early after transplantation preemptively to prevent graft damage, and treatment for established recurrent hepatitis C in the acute, or more commonly, chronic phase. Regardless of the antiviral treatment timing, interferon (INF), especially pegylated-INF (PEG-INF), in conjunction with ribavirin (RBV), is currently accepted as a standard key drug in achieving high sustained viral response (SVR) rate according to the perspectives obtained in nontransplant populations.
Former two strategies, however, have almost been abandoned in Western countries. Pretransplant treatment is severely limited by poor liver function, a high prevalence of nonresponders, severe cytopenia, and complications, including life-threatening infections , and to date, only six studies [153–158] have been published in this phase with differences in the treatment duration (6–14 months versus 2-3 months) and in regimens used (INF only, INF/RBV, or PEG-INF/RBV). Regardless of the approach used, the results are similar, resulting in the prevention of HCV re-infection in about 20% of treated patients with high discontinuation rate and high dose reduction rate . Considering the less severe disease of LDLT recipients as discussed earlier, pretransplant antiviral treatment seems more preferable for LDLT recipients to improve outcome; however, no such trial has been published so far in LDLT setting. This issue also seems remain to be investigated in future studies as with the case in live donor selection issues.
Prophylactic or preemptive antiviral treatment generally means antiviral treatment with INF/PEG-INF and RBV started early posttransplant, without requiring evidence of recurrent hepatitis C. In published studies [159–164] of preemptive antiviral therapy, SVR rates are reported to range from 8% to 34% (5% to 43% for genotype 1 and 14% to 100% for genotypes 2 or 3), with the rates of dose reduction and drug discontinuation are approximately 70% and 30%, respectively, due to the existence of cytopenia, renal dysfunction, rejection, or extrahepatic complications, and high levels of immunosuppression in this time window. The most recently published prospective, multicenter, randomized study (PHOENIX study) by Bzowej et al.  was designed to compare the efficacy, tolerability, and safety of an escalating dose regimen of PEG-INF alpha 2a/RBV for 48 weeks for preemptive antiviral treatment versus no treatment, which showed only 22% SVR in the prophylaxis patients with the rate of marked HCV recurrence at 120 weeks (62% in prophylaxis patients versus 65% in observation patients), and comparable fibrosis progression 120 weeks as well as similar patient/graft survival in both study arms. Dose reduction and discontinuation were required in 70% and 28%, respectively. Based on these results, European and United States transplant societies do not support the routine use of preemptive antiviral therapy.
Consequently, initiating antiviral therapy with PEG-INF/RBV after the confirmation of recurrent hepatitis C in the graft by liver biopsies is the mainstay for the treatment of recurrent disease in Western countries [35, 166–190]. Most of the data come from uncontrolled studies with different designs regarding time to start treatment, regimen used, and follow-up, but treatment duration is generally 48 to 52 weeks. Therefore, the results were also very different, with SVR rates ranging 0% to 56% (median: 33%), discontinuation rates ranging 4% to 58%, and dose reduction rate ranging 28% to 100%. In addition, the survival benefit of the treatment has not been confirmed in most studies so far, and it is compelling to conclude that there is currently no evidence to support the antiviral treatment for recurrent graft hepatitis C due to the lack of clinical benefit and frequent adverse effects, as concluded by the recent Cochrane meta-analysis . On the other hand, recent retrospective cohort studies with a considerable follow-up duration found improved patient/graft survival in patients who obtained an SVR after antiviral treatment [35, 192–194]. Further randomized clinical trials with appropriate trial methodology and adequate follow-up duration are necessary to confirm an actual survival benefit of antiviral treatment.
6. Reports from Japanese LDLT Centers
Although retransplantation is the only potentially curative option for those with decompressed cirrhosis due to recurrent hepatitis C, in contrast to Western countries where re-DDLT is spared as a last resort [195, 196], it is extremely unlikely in Japan to perform retransplantation for patients with recurrent end-stage hepatitis C, if not absolutely impossible. These backgrounds might have led to various modified strategies for the treatment of recurrent disease as best efforts to secure first graft, such as aggressive preemptive antiviral treatment, escalation of dosages, and elongation of treatment duration.
We have reported preemptive INF/RBV treatment for HCV-positive LDLT recipients [161, 197–199]. Preemptive treatment was started just after recipient’s condition had become stable (approximately one month after LDLT) with low-dose INF alpha 2b and RBV (400 mg/day) followed by escalation to PEG-INF (1.5 μg/kg per week) and RBV (800 mg/day) depending on patient’s tolerance. The treatment duration was not settled, and was continued for additional 12 months after the serum HCV-RNA became negative. The response was considered to be SVR provided negative serologic results for another 6 months after discontinuation of therapy. That is, nonstopping peg-INF/RBV approach was applied for non-responders. Among 122 HCV-positive LDLT recipients, 42 (34%) achieved SVR and those with SVR showed significantly improved survival when compared to those without SVR (cumulative 5-year survival rate; 97% versus 66%) .
Kyoto group also reported modified PEG-INF/RBV treatment with individualized extension, while they started antiviral treatment for cases with biopsy-proven recurrent disease [200–202]. They started with PEG-INF (1.5 μg/kg per week) and RBV (400–800 mg/day) for 12 months for all patients with recurrent hepatitis. Then, full dose treatment was continued for additional 8–22 months for those whose serum HCV-RNA became negative within 12 months, while patients who did not become negative for serum HCV RNA within 12 months continued to receive a low-dose PEG-INF (0.5–0.75 μg/kg per week) with or without reduced RBV (200 mg/day) as maintenance treatment. Among 80 patients with recurrent hepatitis C after LDLT, SVR was achieved in 31 (39%), while remaining 49 (61%) received maintenance therapy among those 26 (53%) discontinued. In comparison to fibrosis progression, no difference was observed between SVR group and maintenance treatment group with improved or stable fibrosis in both groups, while those who withdrew from maintenance showed significantly deteriorated fibrosis .
Kyushu group performed antiviral treatment for 80 patients among 106 consecutive HCV-positive recipients, excluding 26 cases of early death, negative HCV RNA, and refusal for treatment . Basically, they started with PEG-INF (0.5 μg/kg per week) and RBV (200 mg/day), then escalated to PEG-INF (1.5 μg/kg per week) and RBV (800 mg/day), with the treatment duration of 48 weeks and over 72 weeks for those with early viral response and for those without it, respectively. They reported overall SVR rate of 35%. They found both significantly severe fibrosis and impaired graft survival in those who did not show viral nor biochemical response.
Other Japanese centers [204–207] have also reported similar modified antiviral treatment with PEG-INF and RBV including dose escalation, treatment for all HCV-positive cases, and extension of treatment. Additionally, simultaneous splenectomy during LDLT operation in an attempt to improve tolerance to antiviral treatment, SVR rate and further graft survival should be noticed [198, 208, 209].
Hepatitis C is here to stay and will remain the most common indication for liver transplantation. In the areas where cadaveric organs are extremely limited like in Japan, indication of LDLT is same as that of DDLT, and recent studies have proved that LDLT can be performed as safely and effectively as DDLT for HCV-infected patients in experienced centers. Further investigation for more effective and tolerable antiviral treatment is warranted to secure the first live donor graft to the possible extent.
|DDLT:||Deceased-donor liver transplantation|
|HCV:||Hepatitis C virus|
|HIV:||Human immunodeficiency virus|
|LDLT:||Living-donor liver transplantation|
|MELD:||Model for end-stage liver disease|
|mTOR:||Mammalian target of rapamycin|
|SVR:||Sustained viral response|
|UNOS/OPTN:||The United Network for Organ Sharing/Organ Procurement and Transplantation Network.|
R. W. Strong, S. V. Lynch, T. H. Ong, H. Matsunami, Y. Koido, and G. A. Balderson, “Successful liver transplantation from a living donor to her son,” New England Journal of Medicine, vol. 322, no. 21, pp. 1505–1507, 1990.View at: Google Scholar
Y. Hashikura, M. Makuuchi, S. Kawasaki et al., “Successful living-related partial liver transplantation to an adult patient,” Lancet, vol. 343, no. 8907, pp. 1233–1234, 1994.View at: Google Scholar
Y. Sugawara and M. Makuuchi, “Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo,” Liver Transplantation, vol. 10, no. 6, pp. 715–720, 2004.View at: Publisher Site | Google Scholar
Y. Sugawara and M. Makuuchi, “Living donor liver transplantation to patients with hepatitis C virus cirrhosis,” World Journal of Gastroenterology, vol. 12, no. 28, pp. 4461–4465, 2006.View at: Google Scholar
M. Berenguer, M. Prieto, J. M. Rayón et al., “Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation,” Hepatology, vol. 32, no. 4, part 1, pp. 852–858, 2000.View at: Google Scholar
L. M. Forman, J. D. Lewis, J. A. Berlin, H. I. Feldman, and M. R. Lucey, “The association between hepatitis C infection and survival after orthotopic liver transplantation,” Gastroenterology, vol. 122, no. 4, pp. 889–896, 2002.View at: Google Scholar
A. Rubin, V. Aguilera, and M. Berenguer, “Liver transplantation and hepatitis C,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 12, pp. 805–812, 2011.View at: Google Scholar
L. S. Belli, A. K. Burroughs, P. Burra et al., “Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study,” Liver Transplantation, vol. 13, no. 5, pp. 733–740, 2007.View at: Publisher Site | Google Scholar
K. M. Olthoff, M. M. Abecassis, J. C. Emond et al., “Outcomes of adult living donor liver transplantation: comparison of the adult-to-adult living donor liver transplantation cohort study and the national experience,” Liver Transplantation, vol. 17, no. 7, pp. 789–797, 2011.View at: Publisher Site | Google Scholar
The Japanese Liver Transplantation Society, “Liver transplantation in Japan. Registry by the Japanese liver transplantation society,” Japanese Journal of Transplantation, vol. 46, no. 6, pp. 524–536, 2011.View at: Google Scholar
P. A. Vagefi, N. L. Ascher, C. E. Freise et al., “Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation,” Liver Transplantation, vol. 18, no. 2, pp. 160–165, 2012.View at: Google Scholar
R. Sreekumar, A. Gonzalez-Koch, Y. Maor-Kendler et al., “Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation,” Hepatology, vol. 32, no. 5, pp. 1125–1130, 2000.View at: Google Scholar
G. V. Papatheodoridis, S. G. Barton, D. Andrew et al., “Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens,” Gut, vol. 45, no. 3, pp. 427–434, 1999.View at: Google Scholar
C. Feray, L. Caccamo, G. J. Alexander et al., “European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group,” Gastroenterology, vol. 117, no. 3, pp. 619–625, 1999.View at: Google Scholar
H. E. Vargas, T. Laskus, L. F. Wang et al., “The influence of hepatitis C virus genotypes on the outcome of liver transplantation,” Liver Transplantation and Surgery, vol. 4, no. 1, pp. 22–27, 1998.View at: Google Scholar
A. W. Avolio, U. Cillo, M. Salizzoni et al., “Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients,” American Journal of Transplantation, vol. 11, no. 12, pp. 2724–2736, 2011.View at: Google Scholar
T. Walter, J. Dumortier, O. Guillaud, V. Hervieu, J. Y. Scoazec, and O. Boillot, “Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center,” Liver Transplantation, vol. 13, no. 2, pp. 294–301, 2007.View at: Publisher Site | Google Scholar
M. R. Charlton, A. Thompson, B. J. Veldt et al., “Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection,” Hepatology, vol. 53, no. 1, pp. 317–324, 2011.View at: Publisher Site | Google Scholar
P. G. Northup, C. K. Argo, D. T. Nguyen et al., “Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a us national transplant registry analysis,” Transplant International, vol. 23, no. 10, pp. 1038–1044, 2010.View at: Publisher Site | Google Scholar
A. T. Burr, Y. Li, J. F. Tseng et al., “Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database,” World Journal of Surgery, vol. 35, no. 7, pp. 1590–1595, 2011.View at: Google Scholar
P. W. Baron, D. Sindram, D. Higdon et al., “Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation,” Liver Transplantation, vol. 6, no. 4, pp. 407–412, 2000.View at: Google Scholar
D. Brandman, A. Pingitore, J. C. Lai et al., “Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus,” Liver Transplantation, vol. 17, no. 12, pp. 1380–1386, 2011.View at: Google Scholar
V. Subramanian, A. B. Seetharam, N. Vachharajani et al., “Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation,” Transplantation, vol. 92, no. 11, pp. 1259–1268, 2011.View at: Google Scholar
P. A. Sheiner, M. E. Schwartz, E. Mor et al., “Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation,” Hepatology, vol. 21, no. 1, pp. 30–34, 1995.View at: Google Scholar
G. B. Klintmalm, G. L. Davis, L. Teperman et al., “A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C,” Liver Transplantation, vol. 17, no. 12, pp. 1394–1403, 2011.View at: Google Scholar
C. Margarit, I. Bilbao, L. Castells et al., “A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C,” Transplant International, vol. 18, no. 12, pp. 1336–1345, 2005.View at: Publisher Site | Google Scholar
T. Kato, J. J. Gaynor, H. Yoshida et al., “Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year,” Transplantation, vol. 84, no. 7, pp. 829–835, 2007.View at: Publisher Site | Google Scholar
L. Lladó, J. Fabregat, J. Castellote et al., “Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study,” Liver Transplantation, vol. 14, no. 12, pp. 1752–1760, 2008.View at: Publisher Site | Google Scholar
P. Martin, R. W. Busuttil, R. M. Goldstein et al., “Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial,” Liver Transplantation, vol. 10, no. 10, pp. 1258–1262, 2004.View at: Publisher Site | Google Scholar
J. G. O'Grady, P. Hardy, A. K. Burroughs et al., “Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years,” American Journal of Transplantation, vol. 7, no. 1, pp. 137–141, 2007.View at: Publisher Site | Google Scholar
G. Levy, G. L. Grazi, F. Sanjuan et al., “12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplantation recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus,” Liver Transplantation, vol. 12, no. 10, pp. 1464–1472, 2006.View at: Publisher Site | Google Scholar
W. D. Irish, S. Arcona, D. Bowers, and J. F. Trotter, “Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database,” American Journal of Transplantation, vol. 11, no. 8, pp. 1676–1685, 2011.View at: Publisher Site | Google Scholar
M. Berenguer, “Risk of extended criteria donors in hepatitis C virus-positive recipients,” Liver Transplantation, vol. 14, supplement 2, pp. S45–S50, 2008.View at: Google Scholar
S. M. Strasberg, T. K. Howard, E. P. Molmenti, and M. Hertl, “Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation,” Hepatology, vol. 20, no. 4, part 1, pp. 829–838, 1994.View at: Google Scholar
R. J. Ploeg, A. M. D'Alessandro, S. J. Knechtle et al., “Risk factors for primary dysfunction after liver transplantation—a multivariate analysis,” Transplantation, vol. 55, no. 4, pp. 807–813, 1993.View at: Google Scholar
R. Hernandez-Alejandro, K. P. Croome, D. Quan et al., “Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts,” Transplantation, vol. 92, no. 6, pp. 686–689, 2011.View at: Google Scholar
A. Humar, K. Horn, A. Kalis, B. Glessing, W. D. Payne, and J. Lake, “Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?” American Journal of Transplantation, vol. 5, no. 2, pp. 399–405, 2005.View at: Publisher Site | Google Scholar
A. Bozorgzadeh, A. Jain, C. Ryan et al., “Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus,” Transplantation, vol. 77, no. 7, pp. 1066–1070, 2004.View at: Google Scholar
H. van Vlierberghe, R. Troisi, I. Colle, S. Ricciardi, M. Praet, and B. de Hemptinne, “Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults,” Transplantation, vol. 77, no. 2, pp. 210–214, 2004.View at: Publisher Site | Google Scholar
L. Guo, M. Orrego, H. Rodriguez-Luna et al., “Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients,” Liver Transplantation, vol. 12, no. 4, pp. 560–565, 2006.View at: Publisher Site | Google Scholar
M. Schmeding, U. P. Neumann, G. Puhl, M. Bahra, R. Neuhaus, and P. Neuhaus, “Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients,” Liver Transplantation, vol. 13, no. 5, pp. 687–692, 2007.View at: Publisher Site | Google Scholar
N. Selzner, N. Girgrah, L. Lilly et al., “The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age,” Liver Transplantation, vol. 14, no. 12, pp. 1778–1786, 2008.View at: Publisher Site | Google Scholar
A. Jain, A. Singhal, R. Kashyap et al., “Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up,” Transplantation, vol. 92, no. 4, pp. 453–460, 2011.View at: Google Scholar
M. Charlton, E. Seaberg, R. Wiesner et al., “Predictors of patient and graft survival following liver transplantation for hepatitis C,” Hepatology, vol. 28, no. 3, pp. 823–830, 1998.View at: Google Scholar
Y. Sugawara, S. Tamura, and N. Kokudo, “Liver transplantation in HCV/HIV positive patients,” World Journal of Gastrointestinal Surgery, vol. 3, no. 2, pp. 21–28, 2011.View at: Google Scholar
J. C. Duclos-Vallee, C. Feray, M. Sebagh et al., “Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus,” Hepatology, vol. 47, no. 2, pp. 407–417, 2008.View at: Google Scholar
J. C. Duclos-Vallee, B. Falissard, and D. Samuel, “Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with a synthetic cohort,” AIDS, vol. 25, no. 13, pp. 1675–1676, 2011.View at: Google Scholar
A. Moreno, C. Cervera, J. Fortun et al., “Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study,” Liver Transplantation, vol. 18, no. 1, pp. 70–81, 2012.View at: Google Scholar
J. Fung, B. Eghtesad, K. Patel-Tom, M. DeVera, H. Chapman, and M. Ragni, “Liver transplantation in patients with HIV infection,” Liver Transplantation, vol. 10, no. 10, supplement 2, pp. S39–S53, 2004.View at: Google Scholar
N. M. Kemmer and K. E. Sherman, “Liver transplantation trends in the HIV population,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3393–3398, 2011.View at: Google Scholar
D. Eurich, S. Boas-Knoop, M. Ruehl et al., “Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation,” Liver Transplantation, vol. 17, no. 3, pp. 289–298, 2011.View at: Publisher Site | Google Scholar
R. Teixeira, S. Pastacaldi, S. Davies et al., “The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation,” Transplantation, vol. 70, no. 10, pp. 1454–1458, 2000.View at: Google Scholar
S. Baid, A. B. Cosimi, M. Lin Farrell et al., “Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal, relationship with hepatitis C virus allograft hepatitis, and impact on mortality,” Transplantation, vol. 72, no. 6, pp. 1066–1072, 2001.View at: Google Scholar
M. Charlton and E. Seaberg, “Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database,” Liver Transplantation and Surgery, vol. 5, no. 4, supplement 1, pp. S107–S114, 1999.View at: Google Scholar
F. Filipponi, F. Callea, M. Salizzoni et al., “Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine,” Transplantation, vol. 78, no. 10, pp. 1488–1495, 2004.View at: Publisher Site | Google Scholar
Y. Calmus, J. R. Scheele, I. Gonzalez-Pinto et al., “Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients,” Liver Transplantation, vol. 8, no. 2, pp. 123–131, 2002.View at: Publisher Site | Google Scholar
P. Neuhaus, P. A. Clavien, D. Kittur et al., “Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial,” Liver Transplantation, vol. 8, no. 2, pp. 132–142, 2002.View at: Publisher Site | Google Scholar
D. R. Nelson, C. Soldevila-Pico, A. Reed et al., “Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation,” Liver Transplantation, vol. 7, no. 12, pp. 1064–1070, 2001.View at: Publisher Site | Google Scholar
R. H. Wiesner, J. S. Shorr, B. J. Steffen, A. H. Chu, R. D. Gordon, and J. R. Lake, “Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C,” Liver Transplantation, vol. 11, no. 7, pp. 750–759, 2005.View at: Publisher Site | Google Scholar
A. Zekry, M. Gleeson, S. Guney, and G. W. McCaughan, “A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection,” Liver Transplantation, vol. 10, no. 1, pp. 52–57, 2004.View at: Publisher Site | Google Scholar
S. Asthana, C. Toso, G. Meeberg et al., “The impact of sirolimus on hepatitis C recurrence after liver transplantation,” Canadian Journal of Gastroenterology, vol. 25, no. 1, pp. 28–34, 2011.View at: Google Scholar
K. M. Olthoff, “Hepatic regeneration in living donor liver transplantation,” Liver Transplantation, vol. 9, no. 10, supplement 2, pp. S35–S41, 2003.View at: Google Scholar
G. T. Everson and J. Trotter, “Role of adult living donor liver transplantation in patients with hepatitis C,” Liver Transplantation, vol. 9, no. 10, supplement 2, pp. S64–S68, 2003.View at: Google Scholar
R. Manez, R. Mateo, J. Tabasco, S. Kusne, T. E. Starzl, and R. J. Duquesnoy, “The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation,” Transplantation, vol. 59, no. 4, pp. 640–642, 1995.View at: Google Scholar
J. A. Carrión, E. Martínez-Bauer, G. Crespo et al., “Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study,” Journal of Hepatology, vol. 50, no. 4, pp. 719–728, 2009.View at: Publisher Site | Google Scholar
J. S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M. R. Charlton, “A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation,” Liver Transplantation, vol. 8, no. 4, pp. 350–355, 2002.View at: Publisher Site | Google Scholar
R. M. Thomas, J. J. Brems, G. Guzman-Hartman, S. Yong, P. Cavaliere, and D. H. van Thiel, “Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation,” Liver Transplantation, vol. 9, no. 9, pp. 905–915, 2003.View at: Publisher Site | Google Scholar
S. Tamura, Y. Sugawara, N. Yamashiki, J. Kaneko, N. Kokudo, and M. Makuuchi, “Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience,” Transplant International, vol. 23, no. 6, pp. 580–588, 2010.View at: Publisher Site | Google Scholar
N. Chalasani, C. Manzarbeitia, P. Ferenci et al., “Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials,” Hepatology, vol. 41, no. 2, pp. 289–298, 2005.View at: Google Scholar
N. Bzowej, D. R. Nelson, N. A. Terrault et al., “PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus,” Liver Transplantation, vol. 17, no. 5, pp. 528–538, 2011.View at: Publisher Site | Google Scholar
B. Roche, M. Sebagh, M. L. Canfora et al., “Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis,” Liver Transplantation, vol. 14, no. 12, pp. 1766–1777, 2008.View at: Publisher Site | Google Scholar
M. Babatin, L. Schindel, and K. W. Burak, “Pegylated-interferon alpha 2b and ribavirin for recurrent hepatities C after liver liver transplantation: from a Canadian experience to recommendations for therapy,” Canadian Journal of Gastroenterology, vol. 19, no. 6, pp. 359–365, 2005.View at: Google Scholar
P. Toniutto, C. Fabris, E. Fumo et al., “Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy,” Journal of Gastroenterology and Hepatology, vol. 20, no. 4, pp. 577–582, 2005.View at: Publisher Site | Google Scholar
M. Biselli, P. Andreone, A. Gramenzi et al., “Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen,” Digestive and Liver Disease, vol. 38, no. 1, pp. 27–32, 2006.View at: Publisher Site | Google Scholar
P. Sharma, J. A. Marrero, R. J. Fontana et al., “Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence,” Liver Transplantation, vol. 13, no. 8, pp. 1100–1108, 2007.View at: Publisher Site | Google Scholar
T. Zimmermann, W. O. Böcher, S. Biesterfeld et al., “Efficacy of an escalating dose regimen of pegylated interferon α-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation,” Transplant International, vol. 20, no. 7, pp. 583–590, 2007.View at: Publisher Site | Google Scholar
I. A. Hanouneh, C. Miller, F. N. Aucejo, R. Lopez, M. K. Quinn, and N. N. Zein, “Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy,” Liver Transplantation, vol. 14, no. 1, pp. 53–58, 2008.View at: Publisher Site | Google Scholar
W. Al-Hamoudi, H. Mohamed, F. Abaalkhail et al., “Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1848–1852, 2011.View at: Publisher Site | Google Scholar
K. S. Gurusamy, E. Tsochatzis, B. R. Davidson, and A. K. Burroughs, “Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation,” Cochrane Database of Systematic Reviews, no. 12, Article ID CD006573, 2010.View at: Google Scholar
B. J. Veldt, J. J. Poterucha, K. D. S. Watt et al., “Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection,” American Journal of Transplantation, vol. 8, no. 11, pp. 2426–2433, 2008.View at: Publisher Site | Google Scholar
M. Berenguer, A. Palau, V. Aguilera, J. M. Rayón, F. S. Juan, and M. Prieto, “Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation,” American Journal of Transplantation, vol. 8, no. 3, pp. 679–687, 2008.View at: Publisher Site | Google Scholar
Y. Ueda, Y. Takada, H. Marusawa, H. Egawa, S. Uemoto, and T. Chiba, “Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation,” Transplantation, vol. 90, no. 6, pp. 661–665, 2010.View at: Publisher Site | Google Scholar
Y. Ueda, H. Marusawa, T. Kaido et al., “Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation,” Journal of Viral Hepatitis, vol. 19, no. 1, pp. 32–38, 2012.View at: Google Scholar
S. Eguchi, M. Takatsuki, A. Soyama et al., “Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation,” Annals of Transplantation, vol. 12, no. 4, pp. 11–15, 2007.View at: Google Scholar
T. Kawaoka, N. Hiraga, S. Takahashi et al., “Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus,” Scandinavian Journal of Gastroenterology, vol. 45, no. 12, pp. 1488–1496, 2010.View at: Publisher Site | Google Scholar